{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:54:11Z","timestamp":1761238451112,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T00:00:00Z","timestamp":1509667200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81270303 and 81470516"],"award-info":[{"award-number":["81270303 and 81470516"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00059-017-4635-5","type":"journal-article","created":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T10:21:15Z","timestamp":1509704475000},"page":"247-256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Genistein attenuates pathological cardiac hypertrophy in vivo and in vitro","Verminderung pathologischer kardialer Hypertrophie in vivo und in vitro durch Genistein"],"prefix":"10.1007","volume":"44","author":[{"given":"Y.","family":"Meng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,3]]},"reference":[{"key":"4635_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.yjmcc.2016.06.001","volume":"97","author":"I Shimizu","year":"2016","unstructured":"Shimizu I, Minamino T (2016) Physiological and pathological cardiac hypertrophy. J\u00a0Mol Cell Cardiol 97:245\u2013262","journal-title":"J Mol Cell Cardiol"},{"issue":"Suppl 1","key":"4635_CR2","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1097\/01.hjh.0000388492.73954.0b","volume":"28","author":"P Finckenberg","year":"2010","unstructured":"Finckenberg P, Mervaala E (2010) Novel regulators and drug targets of cardiac hypertrophy. J\u00a0Hypertens 28(Suppl 1):S33\u2013S38","journal-title":"J Hypertens"},{"key":"4635_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00018-013-1349-6","volume":"71","author":"P Kong","year":"2014","unstructured":"Kong P, Christia P, Frangogiannis NG (2014) The pathogenesis of cardiac fibrosis. Cell Mol Life Sci 71:549\u2013574","journal-title":"Cell Mol Life Sci"},{"key":"4635_CR4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/01926230500419421","volume":"34","author":"YJ Kang","year":"2006","unstructured":"Kang YJ (2006) Cardiac hypertrophy: a\u00a0risk factor for QT-prolongation and cardiac sudden death. Toxicol Pathol 34:58\u201366","journal-title":"Toxicol Pathol"},{"key":"4635_CR5","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00204-015-1477-x","volume":"89","author":"YK Tham","year":"2015","unstructured":"Tham YK, Bernardo BC, Ooi JY, Weeks KL, McMullen JR (2015) Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch Toxicol 89:1401\u20131438","journal-title":"Arch Toxicol"},{"issue":"Suppl A","key":"4635_CR6","doi-asserted-by":"publisher","first-page":"A13","DOI":"10.1253\/circj.CJ-08-0481","volume":"72","author":"T Oka","year":"2008","unstructured":"Oka T, Komuro I (2008) Molecular mechanisms underlying the transition of cardiac hypertrophy to heart failure. Circ\u00a0J 72(Suppl A):A13\u2013A16","journal-title":"Circ J"},{"key":"4635_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.phrs.2009.11.012","volume":"61","author":"A Rohini","year":"2010","unstructured":"Rohini A, Agrawal N, Koyani CN, Singh R (2010) Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res 61:269\u2013280","journal-title":"Pharmacol Res"},{"issue":"8","key":"4635_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nrm1983","volume":"7","author":"J Heineke","year":"2006","unstructured":"Heineke J, Molkentin JD (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7(8):589\u2013600","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4635_CR9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1291\/hypres.25.491","volume":"25","author":"H Takano","year":"2002","unstructured":"Takano H, Zou Y, Akazawa H, Toko H, Mizukami M, Hasegawa H, Asakawa M, Nagai T, Komuro I (2002) Inhibitory molecules in signal transduction pathways of cardiac hypertrophy. Hypertens Res 25:491\u2013498","journal-title":"Hypertens Res"},{"key":"4635_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.yjmcc.2014.02.002","volume":"73","author":"CM Sag","year":"2014","unstructured":"Sag CM, Santos CX, Shah AM (2014) Redox regulation of cardiac hypertrophy. J\u00a0Mol Cell Cardiol 73:103\u2013111","journal-title":"J Mol Cell Cardiol"},{"key":"4635_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1023\/A:1024119224033","volume":"247","author":"T Ravingerova","year":"2003","unstructured":"Ravingerova T, Barancik M, Strniskova M (2003) Mitogen-activated protein kinases: a\u00a0new therapeutic target in cardiac pathology. Mol Cell Biochem 247:127\u2013138","journal-title":"Mol Cell Biochem"},{"key":"4635_CR12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3109\/15376516.2012.666650","volume":"22","author":"SK Maulik","year":"2012","unstructured":"Maulik SK, Kumar S (2012) Oxidative stress and cardiac hypertrophy: a\u00a0review. Toxicol Mech Methods 22:359\u2013366","journal-title":"Toxicol Mech Methods"},{"key":"4635_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.imbio.2016.10.004","volume":"222","author":"K Zhang","year":"2017","unstructured":"Zhang K, Wang Y, Ma W, Hu Z, Zhao P (2017) Genistein improves thyroid function in Hashimoto\u2019s thyroiditis patients through regulating Th1 cytokines. Immunobiology 222:183\u2013187","journal-title":"Immunobiology"},{"key":"4635_CR14","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/nure.12044","volume":"71","author":"GP Nagaraju","year":"2013","unstructured":"Nagaraju GP, Zafar SF, El-Rayes BF (2013) Pleiotropic effects of genistein in metabolic, inflammatory, and malignant diseases. Nutr Rev 71:562\u2013572","journal-title":"Nutr Rev"},{"key":"4635_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00011-003-1182-8","volume":"52","author":"M Verdrengh","year":"2003","unstructured":"Verdrengh M, Jonsson IM, Holmdahl R, Tarkowski A (2003) Genistein as an anti-inflammatory agent. Inflamm Res 52:341\u2013346","journal-title":"Inflamm Res"},{"key":"4635_CR16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1471-4159.2008.05614.x","volume":"107","author":"AE Valsecchi","year":"2008","unstructured":"Valsecchi AE, Franchi S, Panerai AE, Sacerdote P, Trovato AE, Colleoni M (2008) Genistein, a\u00a0natural phytoestrogen from soy, relieves neuropathic pain following chronic constriction sciatic nerve injury in mice: anti-inflammatory and antioxidant activity. J\u00a0Neurochem 107:230\u2013240","journal-title":"J Neurochem"},{"key":"4635_CR17","doi-asserted-by":"publisher","first-page":"888","DOI":"10.4161\/epi.6.7.16315","volume":"6","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Chen H (2011) Genistein, an epigenome modifier during cancer prevention. Epigenetics 6:888\u2013891","journal-title":"Epigenetics"},{"key":"4635_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1039\/C2FO30199G","volume":"4","author":"ER Gilbert","year":"2013","unstructured":"Gilbert ER, Liu D (2013) Anti-diabetic functions of soy isoflavone genistein: mechanisms underlying its effects on pancreatic beta-cell function. Food Funct 4:200\u2013212","journal-title":"Food Funct"},{"key":"4635_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.maturitas.2008.04.003","volume":"59","author":"J Wang","year":"2008","unstructured":"Wang J, Zhang Q, Jin S, He D, Zhao S, Liu S (2008) Genistein modulate immune responses in collagen-induced rheumatoid arthritis model. Maturitas 59:405\u2013412","journal-title":"Maturitas"},{"key":"4635_CR20","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1139\/y2012-068","volume":"90","author":"SK Maulik","year":"2012","unstructured":"Maulik SK, Prabhakar P, Dinda AK, Seth S (2012) Genistein prevents isoproterenol-induced cardiac hypertrophy in rats. Can J Physiol Pharmacol 90:1117\u20131125","journal-title":"Can J Physiol Pharmacol"},{"key":"4635_CR21","doi-asserted-by":"publisher","first-page":"5559","DOI":"10.1111\/bph.13002","volume":"172","author":"W Qin","year":"2015","unstructured":"Qin W, Du N, Zhang L, Wu X, Hu Y, Li X, Shen N, Li Y, Yang B, Xu C, Fang Z, Lu Y, Zhang Y, Du Z (2015) Genistein alleviates pressure overload-induced cardiac dysfunction and interstitial fibrosis in mice. Br J Pharmacol 172:5559\u20135572","journal-title":"Br J Pharmacol"},{"key":"4635_CR22","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/j.1476-5381.2009.00605.x","volume":"159","author":"DF Shen","year":"2010","unstructured":"Shen DF, Tang QZ, Yan L, Zhang Y, Zhu LH, Wang L, Liu C, Bian ZY, Li H (2010) Tetrandrine blocks cardiac hypertrophy by disrupting reactive oxygen species-dependent ERK1\/2 signalling. Br J Pharmacol 159:970\u2013981","journal-title":"Br J Pharmacol"},{"key":"4635_CR23","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1161\/HYPERTENSIONAHA.116.07906","volume":"68","author":"Y Yuan","year":"2016","unstructured":"Yuan Y, Yan L, Wu QQ, Zhou H, Jin YG, Bian ZY, Deng W, Yang Z, Shen DF, Zeng XF, Wang SS, Li H, Tang QZ (2016) Mnk1 (Mitogen-activated protein kinase-interacting kinase 1) deficiency aggravates cardiac remodeling in mice. Hypertension 68:1393\u20131399","journal-title":"Hypertension"},{"key":"4635_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.biopha.2015.10.026","volume":"76","author":"AA Ganai","year":"2015","unstructured":"Ganai AA, Farooqi H (2015) Bioactivity of genistein: a review of in vitro and in vivo studies. Biomed Pharmacother 76:30\u201338","journal-title":"Biomed Pharmacother"},{"key":"4635_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.biopha.2016.05.023","volume":"82","author":"MA Rahman Mazumder","year":"2016","unstructured":"Rahman Mazumder MA, Hongsprabhas P (2016) Genistein as antioxidant and antibrowning agents in vivo and in vitro: a review. Biomed Pharmacother 82:379\u2013392","journal-title":"Biomed Pharmacother"},{"key":"4635_CR26","doi-asserted-by":"publisher","first-page":"16864","DOI":"10.1073\/pnas.0607700103","volume":"103","author":"K Pandya","year":"2006","unstructured":"Pandya K, Kim HS, Smithies O (2006) Fibrosis, not cell size, delineates beta-myosin heavy chain reexpression during cardiac hypertrophy and normal aging in vivo. Proc Natl Acad Sci USA 103:16864\u201316869","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"4635_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pharmthera.2004.04.004","volume":"102","author":"Z Abassi","year":"2004","unstructured":"Abassi Z, Karram T, Ellaham S, Winaver J, Hoffman A (2004) Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Ther 102:223\u2013241","journal-title":"Pharmacol Ther"},{"key":"4635_CR28","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1161\/CIRCRESAHA.109.208314","volume":"106","author":"H Kinoshita","year":"2010","unstructured":"Kinoshita H, Kuwahara K, Nishida M, Jian Z, Rong X, Kiyonaka S, Kuwabara Y, Kurose H, Inoue R, Mori Y, Li Y, Nakagawa Y, Usami S, Fujiwara M, Yamada Y, Minami T, Ueshima K, Nakao K (2010) Inhibition of TRPC6 channel activity contributes to the antihypertrophic effects of natriuretic peptides-guanylyl cyclase\u2014a signaling in the heart. Circ Res 106:1849\u20131860","journal-title":"Circ Res"},{"key":"4635_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/cvr\/cvq308","volume":"89","author":"EE Creemers","year":"2011","unstructured":"Creemers EE, Pinto YM (2011) Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res 89:265\u2013272","journal-title":"Cardiovasc Res"},{"key":"4635_CR30","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1161\/01.RES.0000046452.67724.B8","volume":"91","author":"I Manabe","year":"2002","unstructured":"Manabe I, Shindo T, Nagai R (2002) Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res 91:1103\u20131113","journal-title":"Circ Res"},{"key":"4635_CR31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2174\/1871529X11313020010","volume":"13","author":"Y Purnomo","year":"2013","unstructured":"Purnomo Y, Piccart Y, Coenen T, Prihadi JS, Lijnen PJ (2013) Oxidative stress and transforming growth factor-beta1-induced cardiac fibrosis. Cardiovasc Hematol Disord Drug Targets 13:165\u2013172","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"4635_CR32","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ceca.2005.06.033","volume":"38","author":"P Vangheluwe","year":"2005","unstructured":"Vangheluwe P, Raeymaekers L, Dode L, Wuytack F (2005) Modulating sarco(endo)plasmic reticulum Ca2+ ATPase 2 (SERCA2) activity: cell biological implications. Cell Calcium 38:291\u2013302","journal-title":"Cell Calcium"},{"key":"4635_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.yjmcc.2014.06.018","volume":"75","author":"H Huang","year":"2014","unstructured":"Huang H, Joseph LC, Gurin MI, Thorp EB, Morrow JP (2014) Extracellular signal-regulated kinase activation during cardiac hypertrophy reduces sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 (SERCA2) transcription. J\u00a0Mol Cell Cardiol 75:58\u201363","journal-title":"J Mol Cell Cardiol"},{"key":"4635_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1172\/JCI62839","volume":"123","author":"JH Berlo van","year":"2013","unstructured":"van Berlo JH, Maillet M, Molkentin JD (2013) Signaling effectors underlying pathologic growth and remodeling of the heart. J\u00a0Clin Invest 123:37\u201345","journal-title":"J Clin Invest"},{"key":"4635_CR35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3389\/fphar.2015.00149","volume":"6","author":"M Mutlak","year":"2015","unstructured":"Mutlak M, Kehat I (2015) Extracellular signal-regulated kinases 1\/2 as regulators of cardiac hypertrophy. Front Pharmacol 6:149","journal-title":"Front Pharmacol"},{"key":"4635_CR36","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00204-015-1472-2","volume":"89","author":"EK Kim","year":"2015","unstructured":"Kim EK, Choi EJ (2015) Compromised MAPK signaling in human diseases: an update. Arch Toxicol 89:867\u2013882","journal-title":"Arch Toxicol"},{"key":"4635_CR37","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1161\/01.RES.0000038488.38975.1A","volume":"91","author":"OF Bueno","year":"2002","unstructured":"Bueno OF, Molkentin JD (2002) Involvement of extracellular signal-regulated kinases 1\/2 in cardiac hypertrophy and cell death. Circ Res 91:776\u2013781","journal-title":"Circ Res"},{"key":"4635_CR38","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.2174\/138161211796390976","volume":"17","author":"T Aoyagi","year":"2011","unstructured":"Aoyagi T, Matsui T (2011) Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure. Curr Pharm Des 17:1818\u20131824","journal-title":"Curr Pharm Des"},{"key":"4635_CR39","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1172\/JCI24178","volume":"115","author":"GW Dorn 2nd","year":"2005","unstructured":"Dorn GW 2nd, Force T (2005) Protein kinase cascades in the regulation of cardiac hypertrophy. J\u00a0Clin Invest 115:527\u2013537","journal-title":"J Clin Invest"},{"key":"4635_CR40","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.tcm.2007.01.004","volume":"17","author":"R Kerkela","year":"2007","unstructured":"Kerkela R, Woulfe K, Force T (2007) Glycogen synthase kinase-3beta\u2014actively inhibiting hypertrophy. Trends Cardiovasc Med 17:91\u201396","journal-title":"Trends Cardiovasc Med"},{"key":"4635_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.25934","author":"Z Zhu","year":"2017","unstructured":"Zhu Z, Huang Y, Lv L, Tao Y, Shao M, Zhao C, Xue M, Sun J, Niu C, Wang Y, Kim S, Cong W, Mao W, Jin L (2017) Acute ethanol exposure-induced autophagy-mediated cardiac injury via activation of the ROS-JNK-Bcl-2 pathway. J\u00a0Cell Physiol. \n                    https:\/\/doi.org\/10.1002\/jcp.25934","journal-title":"J Cell Physiol"},{"key":"4635_CR42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1161\/01.HYP.0000105110.12667.F8","volume":"43","author":"GX Zhang","year":"2004","unstructured":"Zhang GX, Kimura S, Nishiyama A, Shokoji T, Rahman M, Abe Y (2004) ROS during the acute phase of Ang II hypertension participates in cardiovascular MAPK activation but not vasoconstriction. Hypertension 43:117\u2013124","journal-title":"Hypertension"},{"key":"4635_CR43","doi-asserted-by":"publisher","first-page":"e103628","DOI":"10.1371\/journal.pone.0103628","volume":"9","author":"L Ma","year":"2014","unstructured":"Ma L, Liu H, Xie Z, Yang S, Xu W, Hou J, Yu B (2014) Ginsenoside Rb3 protects cardiomyocytes against ischemia-reperfusion injury via the inhibition of JNK-mediated NF-kappaB pathway: a\u00a0mouse cardiomyocyte model. PLoS ONE 9:e103628","journal-title":"PLoS ONE"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-017-4635-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-017-4635-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-017-4635-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T06:20:55Z","timestamp":1556864455000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-017-4635-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["4635"],"URL":"https:\/\/doi.org\/10.1007\/s00059-017-4635-5","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"type":"print","value":"0340-9937"},{"type":"electronic","value":"1615-6692"}],"subject":[],"published":{"date-parts":[[2017,11,3]]},"assertion":[{"value":"18 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"Y.\u00a0Meng, Y.\u00a0Zhang, Z.\u00a0Ma, H.\u00a0Zhou, J.\u00a0Ni, H.\u00a0Liao, and Q.\u00a0Tang declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The experimental protocols were approved by the Institutional Animal Care and Use Committee of the Department of Cardiology, Renmin Hospital, Wuhan University. All institutional and national guidelines for the care and use of laboratory animals were followed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}